Putting More Weight on Obesity Trials in Heart Failure

期刊论文
发表日期：

2024年4月15日

查看全文

Josephine Harrington,
Naveed Sattar,
G Michael Felker,
James L. Januzzi,
Carolyn S. P. Lam,
Neha J. Pagidipati,
Ambarish Pandey,
Harriette G. C. Van Spall,
Darren K. McGuire

摘要

Purpose of Review

To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure.

Recent Findings

Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test.

Summary

Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.